狄诺塞麦是干嘛用的？

Bone metastasis treatment drug (denosumab) is better than zoledronic acid. Bone metastasis is a disease with bone damage and pain as the main manifestations caused by the blood metastasis of certain malignant tumors that originate outside bone tissue to bone tissue.

Denosumab (denosumab) is a RANKL inhibitor that can be used for: 1. Prevention of bone-related events caused by bone metastasis of multiple myeloma and solid tumors. 2. Treatment of giant cell tumor of bone in adults or skeletally mature adolescents whose unresectable or surgical resection would lead to serious complications. 3. Treatment of bisphosphonate-resistant hypercalcemia.

For these symptoms, the dosage of denosumab (denosumab) is:

(1) Denosumab (denosumab) can only be injected subcutaneously, not intravenously, intramuscularly or intradermally.

(2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen.

(3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and another 120 mg on day 8 and day 15 in the first month of treatment.

(4) Administer calcium and vitamin D appropriately to prevent hypocalcemia.

(5) Malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and another 120 mg on day 8 and day 15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Patients need to pay attention to the adverse reactions of denosumab (denosumab) injection:

The most common adverse reactions in patients with bone metastases from solid tumors include: weakness/fatigue, nausea, and hypophosphatemia.

Common adverse reactions in patients with giant cell tumor of bone include joint pain, headache, back pain, nausea, limb pain, and fatigue.

If these reactions are not caused by inappropriate use of (denosumab), patients do not need to worry too much. Mild symptoms will subside over time, but severe drug reactions require immediate medical attention.

Recommended related hot articles: /newsDetail/77973.html